2 completed, 2 terminated, 1 recruiting, 1 unknown. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Receptors, Fc: new trials by email Literature Review of Receptors, Fc trials Research Report on Receptors, Fc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide - Chronic Lymphocytic Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2019-05-15 | 2019-06-10 |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | Hackensack Meridian Health | 21 | 2012-02-22 | 2026-04-03 |
| Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project low-dose FCR - Chronic Lymphocytic Leukemia | Unknown | Czech CLL Study Group | 200 | 2011-03-01 | 2014-06-05 | |
| Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Lumiliximab + FCR, FCR - Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Biogen | 40 | 2008-02-01 | 2015-10-02 |
| Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) FCR + Lumiliximab, FCR - Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Biogen | 627 | 2006-11-01 | 2015-10-02 |
| Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Lumiliximab with FCR - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Biogen | 31 | 2004-03-01 | 2015-10-02 |
Leukemia, Lymphocytic, Chronic, B-Cell (6)
Biogen (3) · Czech CLL Study Group (1) · Hackensack Meridian Health (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (4) · Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · France (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · China (1) · Germany (1) · Greece (1) · India (1)
Andre Goy, MD (1) · Zengjun Li (1)
PMID 19843887, PMID 22591390, PMID 25130401, PMID 33618437, PMID 41497516